158 related articles for article (PubMed ID: 33861731)
1. Effects of Incretin-based Therapy on High-sensitivity C-reactive Protein in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Wu Y; Lu Y; Yang S; Zhang Q
Rev Invest Clin; 2020 Oct; 73(5):. PubMed ID: 33861731
[TBL] [Abstract][Full Text] [Related]
2. The effects of incretin-based therapies on β-cell function and insulin resistance in type 2 diabetes: A systematic review and network meta-analysis combining 360 trials.
Wu S; Gao L; Cipriani A; Huang Y; Yang Z; Yang J; Yu S; Zhang Y; Chai S; Zhang Z; Sun F; Zhan S
Diabetes Obes Metab; 2019 Apr; 21(4):975-983. PubMed ID: 30536884
[TBL] [Abstract][Full Text] [Related]
3. Neurological Manifestation of Incretin-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
Gao L; Yu S; Cipriani A; Wu S; Huang Y; Zhang Z; Yang J; Sun Y; Yang Z; Chai S; Zhang Y; Ji L; Zhan S; Sun F
Aging Dis; 2019 Dec; 10(6):1311-1319. PubMed ID: 31788342
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.
Campbell RK
Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040
[TBL] [Abstract][Full Text] [Related]
6. Effects of Incretin-based Therapies on Weight-related Indicators among Patients with Type 2 Diabetes: A Network Meta-analysis.
Xu L; Yu SQ; Gao L; Huang Y; Wu SS; Yang J; Sun YX; Yang ZR; Chai SB; Zhang Y; Ji LN; Sun F; Zhan SY
Biomed Environ Sci; 2020 Jan; 33(1):37-47. PubMed ID: 32029057
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review.
Aroda VR; Henry RR; Han J; Huang W; DeYoung MB; Darsow T; Hoogwerf BJ
Clin Ther; 2012 Jun; 34(6):1247-1258.e22. PubMed ID: 22608780
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis.
Howse PM; Chibrikova LN; Twells LK; Barrett BJ; Gamble JM
Am J Kidney Dis; 2016 Nov; 68(5):733-742. PubMed ID: 27528374
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl-peptidase-4 inhibitors have anti-inflammatory effects in patients with type 2 diabetes.
Xie D; Wang Q; Huang W; Zhao L
Eur J Clin Pharmacol; 2023 Oct; 79(10):1291-1301. PubMed ID: 37493797
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of the safety of incretin-based therapies in type 2 diabetes.
Evans M; Bain SC; Vora J
Expert Rev Endocrinol Metab; 2016 Mar; 11(2):217-232. PubMed ID: 30058866
[TBL] [Abstract][Full Text] [Related]
11. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
Cornell S
J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials.
Tran S; Retnakaran R; Zinman B; Kramer CK
Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():68-76. PubMed ID: 29364587
[TBL] [Abstract][Full Text] [Related]
14. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
15. Effect of ginger (Zingiber officinale) on inflammatory markers: A systematic review and meta-analysis of randomized controlled trials.
Morvaridzadeh M; Fazelian S; Agah S; Khazdouz M; Rahimlou M; Agh F; Potter E; Heshmati S; Heshmati J
Cytokine; 2020 Nov; 135():155224. PubMed ID: 32763761
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Blood Levels of C-Reactive Protein Marker in Obstructive Sleep Apnea: A Systematic Review, Meta-Analysis and Meta-Regression.
Imani MM; Sadeghi M; Farokhzadeh F; Khazaie H; Brand S; Dürsteler KM; Brühl A; Sadeghi-Bahmani D
Life (Basel); 2021 Apr; 11(4):. PubMed ID: 33921787
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
Amori RE; Lau J; Pittas AG
JAMA; 2007 Jul; 298(2):194-206. PubMed ID: 17622601
[TBL] [Abstract][Full Text] [Related]
18. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
Li L; Shen J; Bala MM; Busse JW; Ebrahim S; Vandvik PO; Rios LP; Malaga G; Wong E; Sohani Z; Guyatt GH; Sun X
BMJ; 2014 Apr; 348():g2366. PubMed ID: 24736555
[TBL] [Abstract][Full Text] [Related]
19. Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy.
Goldney J; Sargeant JA; Davies MJ
Diabetologia; 2023 Oct; 66(10):1832-1845. PubMed ID: 37597048
[TBL] [Abstract][Full Text] [Related]
20. Effects of incretin-based therapies on β-cell function in type 1 diabetes mellitus: a systematic review and meta-analysis.
Wu Y; Lu Y; Yang S; Zhang Q
J Int Med Res; 2021 Dec; 49(12):3000605211066306. PubMed ID: 34939442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
